XML 82 R9.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities:    
Net loss $ (100,507) $ (93,612)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 134 111
Stock-based compensation 8,527 7,102
Change in fair value of tranche rights 4,796 0
Fees expensed as part of January 2024 Financing 1,690 0
Foreign currency loss 30 523
Changes in operating assets and liabilities:    
Other current assets and prepaid expenses 1,863 3,858
Accounts payable 3,145 817
Other liabilities 416 96
Accrued expenses (4,860) 10,277
Net cash used in operating activities (84,766) (70,828)
Cash flows from investing activities:    
Sales of Investments-other 0 9,796
Purchases of property and equipment (264) (334)
Net cash provided by (used in) investing activities (264) 9,462
Cash flows from financing activities:    
Proceeds from January 2024 Financing, net of issuance costs 74,273 0
Proceeds from public offering of common stock through At The Market offering, net of issuance costs 191 853
Proceeds from shares issued in connection with the Company's employee stock purchase plan 77 129
Proceeds from the exercise of pre-funded warrants 0 51
Net cash provided by financing activities 74,541 1,033
Effect of exchange rate changes on cash and cash equivalents (517) 262
Net change in cash and cash equivalents (11,006) (60,071)
Cash and cash equivalents, beginning of year 46,674 106,745
Cash and cash equivalents, end of year 35,668 46,674
Supplemental disclosure of noncash investing and financing activities:    
Conversion of tranche rights liability to equity upon increase in authorized shares 28,396 0
Operating lease right-of use asset obtained in exchange for lease obligation $ 448 $ 544